Skip to Main Content

Author Details

Amy L Cummings
university of california los angeles School of Medicine
2014
17
8
PMIDPaper TitleJournal TitlePublished Year
35881197Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.Cancer Immunol Immunother2023
35881197Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.Cancer Immunol Immunother2023
37451404Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.J Thorac Oncol2023
37068173Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Cancer Discov2023
36923158Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib.JTO Clin Res Rep2023
37532930Consent document translation expense hinders inclusive clinical trial enrolment.Nature2023
37532930Consent document translation expense hinders inclusive clinical trial enrolment.Nature2023
37451404Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.J Thorac Oncol2023
37068173Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Cancer Discov2023
36923158Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib.JTO Clin Res Rep2023
36426286The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.JTO Clin Res Rep2022
36426286The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.JTO Clin Res Rep2022
34108179A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.Clin Cancer Res2021
34108179A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.Clin Cancer Res2021
34507111Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.Lung Cancer2021
34507111Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.Lung Cancer2021
32450595Targeted Therapy for Non-Small Cell Lung Cancer.Semin Respir Crit Care Med2020
32450595Targeted Therapy for Non-Small Cell Lung Cancer.Semin Respir Crit Care Med2020
35121931Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.Nat Cancer2020
35121931Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.Nat Cancer2020
31737507KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment.Transl Lung Cancer Res2019
31737507KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment.Transl Lung Cancer Res2019
32038925KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit.Transl Lung Cancer Res2019
32038925KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit.Transl Lung Cancer Res2019
29416316Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.Drug Des Devel Ther2018
29874546A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.J Thorac Oncol2018
30652613Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation.JCO Clin Cancer Inform2018
29416316Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.Drug Des Devel Ther2018
29874546A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.J Thorac Oncol2018
30652613Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation.JCO Clin Cancer Inform2018
29372100The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?Cancer Biol Med2017
29372100The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?Cancer Biol Med2017
24246352Thyroid carcinoma metastases to axillary lymph nodes: report of two rare cases of papillary and medullary thyroid carcinoma and literature review.Endocr Pract2014
24246352Thyroid carcinoma metastases to axillary lymph nodes: report of two rare cases of papillary and medullary thyroid carcinoma and literature review.Endocr Pract2014
  • 1 - 34 of 34

Recommended Authors

Philip E Lammers
Baptist Cancer Center
Career Start Year 2013
Number of shared co-authors 0
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 0
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Gareth Rivalland
Auckland City Hospital
Career Start Year 2010
Number of shared co-authors 0
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 4
Saiama N Waqar
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 4
Puey Ling Chia
Lee Kong Chian School of Medicine, Nanyang Technological University
Career Start Year 2009
Number of shared co-authors 0
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 1
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 0
Paul Wheatley-Price
The Ottawa Hospital Research Institute
Career Start Year 2005
Number of shared co-authors 0
Arun Rajan
Center for Cancer Research, National Cancer Institute
Career Start Year 2005
Number of shared co-authors 0
Hussein A Tawbi
MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Lecia V Sequist
Massachusetts General Hospital Cancer Center, Harvard Medical School
Career Start Year 2003
Number of shared co-authors 5
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 1
Fiona Blackhall
The University of Manchester
Career Start Year 2000
Number of shared co-authors 0
Daniel Morgensztern
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 4
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 4
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Career Start Year 1999
Number of shared co-authors 9
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 2
Cheryl Ho
University of British Columbia
Career Start Year 1995
Number of shared co-authors 0
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 2
Richard W Joseph
Mayo Clinic Hospital
Career Start Year 1994
Number of shared co-authors 3
Gregory J Riely
Memorial Sloan Kettering Cancer Center
Career Start Year 1994
Number of shared co-authors 8
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 0
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 0
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 3
Pasi A J??nne
Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 3
Roy S Herbst
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 6
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 5
Hira Rizvi
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Career Start Year 1978
Number of shared co-authors 5

Collaborators

Edward B Garon
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 10
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Co-authored papers 7
Aaron Lisberg
Jonsson Comprehensive Cancer Center, university of california los angeles
Co-authored papers 5
Jaklin Gukasyan
David Geffen School of Medicine at the University of California los angeles
Co-authored papers 3
James Carroll
David Geffen School of Medicine at the University of California los angeles
Co-authored papers 3
Tristan Grogan
University of California Los Angeles
Co-authored papers 3
Marshall L Spiegel
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 3
David Elashoff
David Geffen School of Medicine at University of California los angeles
Co-authored papers 2
Zorawar S Noor
David Geffen School of Medicine at university of california los angeles
Co-authored papers 2
Charlene M Fares
David Geffen School of Medicine at the University of California los angeles
Co-authored papers 1
Collin M Blakely
University of California san francisco
Co-authored papers 1
Leylah M Drusbosky
College of Medicine, University of Florida
Co-authored papers 1
Izak Faiena
Columbia University Medical Center
Co-authored papers 1
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Benjamin Bachrach
David Geffen School of Medicine at the University of California los angeles
Co-authored papers 1
Steven M Dubinett
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Drew Moghanaki
University of California Los Angeles
Co-authored papers 1
Gemalene Sunga
The University of Texas Health Science Center at Houston School of Dentistry
Co-authored papers 1
Jason W Chan
University of California San Francisco
Co-authored papers 1
James K Hicks
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 1
Debory Li
David Geffen School of Medicine at the University of California los angeles
Co-authored papers 1
Maura Rossetti
University of California Los Angeles
Co-authored papers 1
Alex A T Bui
Co-authored papers 1
Jesse M Zaretsky
University of California los angeles
Co-authored papers 1
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 1
Alexandra Drakaki
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Arjan Gower
David Geffen School of Medicine at University of California at Los Angeles
Co-authored papers 1
Subba R Digumarthy
Massachusetts General Hospital, USA Harvard Medical School
Co-authored papers 1
Karim Chamie
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Dan Ruan
Zhongshan Hospital, Fudan University
Co-authored papers 1
Release 1.2